Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATHENA: rucaparib and nivolumab maintenance after first-line platinum chemotherapy in newly diagnosed ovarian cancer
MOH_2019-01-29_003578Phase 3Active, not recruiting
- Sponsor
- Clovis Oncology
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rucaparib and nivolumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (4 arms), sponsored by Clovis Oncology. Started Jan 2019; status: active, not recruiting.
02
Drugs
rucaparibnivolumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on MOH_2019-01-29_003578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-01-29_003578.